HeartSciences Inc. filed 3 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-07-10. Each change below is quoted from the filing and linked to it.
Every change, newest first
Reported
While considered reasonable by HeartSciences as of the date of this Current Report, such statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance, or achievements to be materially different from those expressed or implied by such forward-looking statements, including, but not limited to: the occurrence of any event, change, or other circumstances that could give rise to the right of one or both of the parties to terminate the Merger Agreement the possibility that the Transactions do not clo
Reported
Employment Agreement Amendment with Andrew Simpson In connection with the Transactions, on June 22, 2026, HeartSciences entered into an amendment (the " Simpson EA Amendment ") to the Employment Agreement, dated as of April 5, 2022 (the " Simpson Employment Agreement "), with Mr. Simpson, HeartSciences' current Chief Executive Officer and Chairman of the Board of Directors (the " Board "), to provide certain revisions to the definitions of "Just Cause" and "Constructive Termination" (each as defined in the Simpson EA Amendment).
Reported
(a)(b) On April 1, 2026, Mark Hilz, Chief Operating Officer, Corporate Secretary and member of the Board of Directors of HeartSciences Inc. (the "Company") passed away at the age of 67 , f ollowing a period of illness.
Find people with the same kind of experience as the senior executive at HeartSciences Inc., with the record behind each one.
Find candidates like senior executive at HeartSciences Inc.New leaders review vendors and budgets in their first months. Get an alert the next time HeartSciences Inc. is in the news or changes leadership.
Get an alert when HeartSciences Inc. changes leadershipTools for this story
Each opens in a new tab, filled in for HeartSciences Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.